We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BD Introduces Smart Connected Robotics to Automate Microbial Identification

By LabMedica International staff writers
Posted on 10 Jan 2022

Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its BD Kiestra IdentifA system, which is designed to automate the preparation of microbiology bacterial identification testing.

Identifying the microorganism that is causing an infection is a labor-intensive process. With the BD Kiestra IdentifA, the lab technician uses BD Synapsys informatics to select discrete bacterial colonies from a digital plate image. Sophisticated robotics then physically pick those selected organisms and prepare the sample for specific identification testing. By automating what are typically cumbersome manual steps, the BD Kiestra IdentifA may reduce the potential for human error when preparing samples for bacterial identification and produce more accurate diagnoses for patients. Streamlining processes also enables lab technicians to focus their time and expertise on higher-value tasks.


Image: BD Kiestra IdentifA system (Photo courtesy of Becton, Dickinson and Company)
Image: BD Kiestra IdentifA system (Photo courtesy of Becton, Dickinson and Company)

BD Kiestra IdentifA is the only FDA-cleared solution that is available as part of a track-connected system for lab automation to support specimen preparation workflows for routine and challenging isolate types. The integration of the BD Synapsys Informatics solution with the BD Kiestra IdentifA, in combination with matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) mass spectrometry, can yield more rapid and accurate identification of bacteria and yeasts to aid clinician treatment decisions.

"The BD Kiestra IdentifA system transforms the manual workflow into one that is standardized, automated and digitized," said Greg Miziolek, vice president and general manager of the U.S. region for BD Integrated Diagnostic Solutions. "Mass spectrometry methods, including MALDI-ToF technology, have innovated and advanced microbial identification in clinical microbiology but often require a significant number of process steps and hands-on-time. The BD Kiestra IdentifA system uses automated colony picking and MALDI-ToF spotting to reduce time to pathogen identification, which in turn can help improve patient management."

Related Links:
Becton, Dickinson and Company 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Latest Microbiology News

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Mouth Bacteria Test Could Predict Colon Cancer Progression

Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection